Greenwood Capital Associates LLC Has $467,000 Holdings in Incyte Co. (NASDAQ:INCY)

Greenwood Capital Associates LLC raised its position in Incyte Co. (NASDAQ:INCY) by 3.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,765 shares of the biopharmaceutical company’s stock after purchasing an additional 219 shares during the period. Greenwood Capital Associates LLC’s holdings in Incyte were worth $467,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group bought a new stake in Incyte during the third quarter valued at $30,000. R Squared Ltd bought a new stake in shares of Incyte during the 4th quarter valued at about $30,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Incyte during the third quarter worth approximately $33,000. Cromwell Holdings LLC increased its holdings in Incyte by 101.1% in the third quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 283 shares in the last quarter. Finally, Groupama Asset Managment lifted its stake in Incyte by 11.4% in the third quarter. Groupama Asset Managment now owns 59,597 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 6,105 shares during the period. 96.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on INCY. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. Bank of America raised shares of Incyte from a “neutral” rating to a “buy” rating and lifted their price target for the company from $68.00 to $90.00 in a research note on Tuesday, October 29th. Citigroup increased their price objective on shares of Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. UBS Group assumed coverage on Incyte in a research report on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of Incyte in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $75.71.

Incyte Stock Performance

NASDAQ:INCY opened at $74.12 on Wednesday. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $71.83 and its 200 day simple moving average is $68.93. The stock has a market cap of $14.28 billion, a P/E ratio of 529.47, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70.

Insider Buying and Selling

In other Incyte news, EVP Vijay K. Iyengar sold 6,043 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the sale, the executive vice president now directly owns 30,658 shares in the company, valued at approximately $2,311,000.04. The trade was a 16.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven H. Stein sold 12,352 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares of the company’s stock, valued at $4,867,831.23. The trade was a 15.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 19,695 shares of company stock worth $1,444,356 in the last three months. 17.60% of the stock is owned by corporate insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.